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Summary
Introduction: In this study, a serial day rapid kindling protocol was used to fully kindle
rats in a matter of days. Subsequently, the anticonvulsant profile of a relatively new
anti-epileptic drug, topiramate, was evaluated in a cross-over design to further
validate this rapid kindling model.
Methods: Rats were kindled during three consecutive days, according to the serial day
rapid kindling protocol. Topiramate was tested at a dose of 100 mg/kg, i.p., over the
next 2 days using a cross-over design. The stability of the kindled statewas evaluated in
all rats during two retest paradigms. During the drug-testing procedure, rats received a
single i.p. injection of either topiramate or verhicle. Starting 1 h later the rats received
additional kindling stimulations during which their response was measured.
Results: Serial day rapid kindling induced a long lasting and stable fully kindled state
that allowed for the anti-epileptic drug screening procedure. Topiramate reduced both
the afterdischarge duration and ameliorated seizure semiology in the kindled rats.
Discussion: Serial day rapid kindling provided a tool to rapidly kindle rats in 3 days.
Using a cross-over design, clear indications on anti-epileptic activity of a given drug can
be determined using few laboratory animals.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +32 9 2403355;
fax: +32 9 2403360.
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Topiramate (TPM; 2,3:4,5-bis-O-[1-methylethyli-
dene]-b-D-fructopyranose sulfamate) is a relatively
new anti-epileptic drug (AED) that is structurally
distinct from other AEDs. It was originally derived. Published by Elsevier Ltd. All rights reserved.
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project aimed at blocking gluconeogenesis, but was
later on pursued for anticonvulsant properties
because of its structural comparison to acetazola-
mide.1,2
In a clinical setting, TPM has been shown to
reduce seizure frequency without producing serious
side-effects in various types of partial and general-
ized epilepsy.1
Its mechanism of action seems diverse and has not
yet been fully elucidated. TPM has been shown to
block voltage-dependant Na+-channels, to enhance
inhibitory neurotransmission, to antagonise a kainate
(KA) subtype of the glutamate receptor and to inhibit
erythrocyte carbonic anhydrase–—although this is
considered to be more relevant to TPM’s side effects
than to its antiseizure activity.1—4
During the preclinical evaluation procedure, TPM
was shown to display anticonvulsive effects in var-
ious animal models of epilepsy. In the traditional
maximal electroshock (MES) test in mice and rats,
TPM blocked seizure spread with a potency similar
to the effect of established AEDs such as phenytoin
(PHT) and carbamazepine (CBZ).4 In animal models
where chemoconvulsants such as pentylenetetra-
zole, bicuculline or picrotoxin were administered,
TPM proved to be a weak or ineffective blocker of
seizure generation, although it did significantly
raise the seizure threshold.4,5 TPM was effective
against both tonic and absence-like seizures in
spontaneously epileptic rats (SERs) and against
provoked audiogenic seizures in DBA/2 mice.6
TPM has also been shown to effectively reduce
audiogenic tonic and clonic seizures and episodes
of wild running in a post-ischemiamodel of epilepsy
in rats.7 In rats displaying spontaneous seizures
following kainic acid-induced status epilepticus,
TPM displayed significant and dose-dependent
anti-epileptic effects.8
At least two studies on the effect of TPM in
amygdala-kindled rats have shown a significant
reduction of both the afterdischarge duration
(ADD) and seizure severity score at various doses
following intraperitoneal (i.p.) and oral (p.o.)
administration.9,10 In traditional electrical kindling,
daily suprathreshold stimulation through an
implanted electrode (usually in one of the limbic
structures) triggers focal epileptiform activity that
eventually evolves into full-blown complex partial
seizures over the course of two or more weeks.11
Kindling is widely used as a screening tool in AED
discovery, albeit as one of the more progressed
phases in anticonvulsant testing due to its laborious
nature. Nevertheless, it is considered as a highly
predictive model of anti-epileptic properties in
potential AED.In this study, the serial day rapid kindling with
recurrent hippocampal seizures (RKRHS) protocol
was used to fully kindle rats in a matter of days
instead of weeks.12,13 Following verification of the
fully kindled state during two retest paradigms, the
anticonvulsant effect of a single i.p. injection of
TPM was assessed in these rats.Methods
Animals
Twelve male Sprague-Dawley rats (250 g; Charles
River Laboratories, Brussels, Belgium) were origin-
ally included in this study. The animals were housed
under environmentally controlled conditions (12 h
light/dark cycles, temperature between 20 8C and
22 8C) at the Ghent University Hospital Animal Facil-
ity. Food and water were supplied ad libitum. All
animals were treated according to the guidelines
approved by the European Ethics Committee
(decree 86/609/CEE) and the study protocol was
approved by the Experimental Animal Ethics Com-
mittee of the Ghent University Hospital.
Electrode implantation
The rats were anaesthetized with a mixture of
ketamine and xylazine (80 mg/kg and 7.5 mg/kg,
respectively, i.p.). The rats then were implanted
with a bipolar stimulation electrode in the dentate
gyrus of the right dorsal hippocampus (stereotaxic
coordinates relative to bregma: 3.9 mm along the
anteroposterior axis, 1.7 mm along themediolateral
axis and 4.0 mm along the dorsoventral axis),
monopolar recording electrodes in the left and right
hippocampus (stereotaxic coordinates relative to
bregma: 5.6 mm along the anteroposterior axis,
+ or 4.6 mm along the mediolateral axis and
7.4 mm along the dorsoventral axis) and three
epidural recording electrodes placed above the left
and right os frontale (recording electrodes) and in
the centre of the os occipitale (ground electrode).14
Electrode manufacturing details have been pre-
viously published.15 The EEG electrodes were fixed
to the skull with dental acrylic cement (Simplex
Rapid powder and liquid; Kemdent, Wiltshire, Uni-
ted Kingdom).
Kindling protocol
All experiments were carried out using a custom
built video-EEG monitoring unit and an isolated
constant current stimulator. One week after sur-
gery, experiments were started. The rats were
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the serial day RKRHS protocol. They received 12
stimulations daily, each stimulation consisting of a
10 s train of 1 ms biphasic square wave pulses at
400 mA and 20 Hz. Consecutive stimulations were
spaced 30 min apart and the kindling response was
evaluated both on the EEG and semiogically.
EEG recordings were performed starting 1 min
before each kindling stimulus (baseline recording)
and ending 1 min after seizure termination (ictal
and postictal recording). Ictal electrographic spik-
ing activity with an amplitude of at least twice the
baseline activity and originating immediately fol-
lowing stimulation was considered as an after-
discharge (AD). Primary hippocampal ADs were
recorded over the bipolar recording electrode in
the right hippocampus and their duration was mea-
sured off-line. The severity of the kindled seizures
and the seizure semiology were scored following
visual inspection of the animals starting 1 min
before the kindling stimulus (baseline behavior)
and ending 1 min after seizure termination (ictal
and postictal behavior). Seizure semiology was
scored by two (unblinded) scientists, who each gave
their own estimate of the seizure stage. When
anomalies between both opinions were noted, these
were resolved through thorough discussion between
the researchers to give a clear indication on seizure
stage. Mean seizure severity score was determined
according to a modified version of the scale of
Racine. The scale of Racine was originally developed
for amygdala kindling, while kindling of the hippo-
campus gives rise to slightly different ictal beha-
vior.16 Rats do not display the typical stage 1 and
stage 2 seizures as described in the scale of Racine,
but wet dog shakes interlaced with oral and facial
automatisms instead.16 These subtle differences
between amygdala and hippocampal kindling prob-
ably reflect activation of different networks within
the limbic structures and therefore, seizures were
graded according to an adjusted version of the scale
of Racine16: Stage 1—2 seizures represented wet dog
shakes, accompanied by both head nodding (stage 1)
and chewing (stage 2). Stage 3 seizures were iden-
tified as unilateral myoclonus in the forepaws while
stage 4 seizures were hallmarked by bilateral myo-
clonus and rearing. Stage 5 seizures equaled rearing
and falling with tonic—clonic convulsions.
Retest paradigm
Following completion of the kindling protocol during
the three consecutive days, the rats were randomly
assigned to two groups: group A and group B. Retest
paradigms were performed in each group of rats
on the fourth and fifth day of the experiment,preceding the drug administration protocol, to ver-
ify the kindled state of the rats. Retest stimulations
were numbered from 1 to 12; Retest Stimulations 1—
6 were performed on day four of the experiment,
Retest Stimulations 7—12 on day five of the experi-
ment. During both paradigms, all rats received six
kindling stimulations, spaced 30 min apart. Rats
that consistently responded with stage 5 seizures
starting from the second retest stimulation were
identified as fully kindled. Rats that did not display
consistent stage 5 seizures were removed from the
experiment (n = 1).
Cross-over design
Following Retest Stimulations 1—6 on day four of the
experiment, rats from group A received a single i.p.
TPM injection while rats from group B were injected
with vehicle. Following Retest Stimulations 7—12 on
day five of the experiment, rats from group A
received only vehicle while rats from group B were
administered TPM 100 mg/kg, i.p.
Drug administration and assessment of the
anti-epileptic effect of TPM
Vehicle consisted of saline (2 ml/kg, 0.9% NaCl)
diluted with 5% ethanol. TPM (100 mg/kg) was dis-
solved in vehicle and was always administered as a
single i.p. injection. This dose of TPM (100 mg/kg,
i.p.) was chosen according to the clinical dosage
range in patients and based on reports of the phar-
macodynamic profile of TPM as established in amyg-
dala-kindled rats.2,10
One hour following administration of either TPMor
vehicle, six additional kindling stimulations were
administered spaced 30 min apart, during which
ADD and seizure semiology of the rats were moni-
tored. These postdrug stimulations were again num-
bered from 1 to 12; Postdrug Stimulations 1—6 were
performed on day four of the experiment, Postdrug
Stimulations 7—12 on day five of the experiment.
Blood sampling and determination of TPM
concentrations in rat plasma
One hour following either TPM or vehicle adminis-
tration, blood samples were obtained through lat-
eral tail vein punction. Blood was sampled in a
volume of 0.5 ml per rat, stored in an ice-cooled
eppendorf vial and centrifuged at 2000  g for
20 min at 4 8C to separate the fractions. Plasma
was extracted using a micropipette in a volume of
250—400 ml/rat. The samples were then stored in a
cryovial, snap-frozen at80 8C and stored in a deep
freezer at 20 8C.
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the Toxicology Department of AZ St.-Jan (Bruges,
Belgium) and analyzed using gas chromatography
mass spectrometry (GCMS) analysis under supervi-
sion of Prof. Danielle Borrey.
The plasma concentration of TPM, in plasma
taken 1 h following i.p. injection of the drug, was
determined at 109.3  3.8 mg/ml.
Statistical analyses
For statistical processing, data from the kindling
acquisition period was pooled between all eight
rats. Data from day four and day of the experiment
were processed for both groups of rats separately. To
validate the stability of the kindled state, averaged
results from Retest Stimulations 1—6 were com-
pared to those of Retest Stimulations 7—12 per
group of rats. To evaluate the effect of the TPM,
averaged results per group of rats from Postdrug
Stimulation 1—6 and Postdrug Stimulation 7—12
were compared to those of Retest Stimulation
1—6 and Retest Stimulation 7—12, respectively.
Results from Retest Stimulation 1 and 7 and from
Postdrug Stimulation 1 and 7 were omitted from
statistical analyses because these were considered
build-up or rekindling stimulations, during which all
rats displayed milder seizure activity.Figure 1 Changes in ADD throughout the experiment.All data is presented as mean  standard error of
the mean and was processed using statistical ana-
lyses software (SPSS; SPSS Belux, Brussels, bel-
gium). To process the ADD, one-way ANOVA was
used (parametric data, verified through a Kolgo-
morov—Smirnov test for normal distribution and a
Levene test for homogeneity of variances). To com-
pare seizure stages, the Mann—Whitney U-test was
used (non-parametric data) combined with the
Wilcoxon signed rank test.Results
Out of the twelve rats that underwent surgery, eight
were selected for the experiment based on general
health of the animal, quality of the EEG recordings
and their response to a test stimulation. These eight
rats showed epileptiform activity on the EEG that
became noticeable as an AD, increasing from amean
duration of 23.2  3.1 s during the first kindling
stimulation to a maximum of 117.1  12.2 s at the
end of the second day of kindling (24 stimulations)
(Fig. 1). Subsequently, mean ADD showed a decreas-
ing trend towards 64.8  7.6 s during the last sti-
mulation of the kindling acquisition paradigm
(Fig. 1). The increase in ADD was accompanied by
noticeable changes in the behavior of the animals;RS = retest stimulation. PD = postdrug stimulation.
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Figure 2 Changes in seizure severity score throughout the experiment. RS = retest stimulation. PD = postdrug
stimulation.wet dog shakes, head nodding, twitching of the
vibrissae and chewing became noticeable after
the first stimulation (Fig. 1). As demonstrated in
Fig. 2, rats displayed mostly stage 1—2 seizures
during the first day of kindling (median seizure rank:
stage 1—2, Wilcoxon). All rats showed a progressive
worsening of seizure semiology: during the second
day of the protocol, median seizure rank had
increased to stage 4 and during the third day median
seizure rank had risen to stage 5 (Fig. 2) (Wilcoxon).
Following completion of the kindling acquisition
protocol, the eight rats were randomly divided into
two groups; group A and group B. Initially, each
group consisted of four rats. Results from the retest
paradigms performed on day four and five of the
experiment did not reveal significant differences in
the kindled state for either group A or group B. Mean
ADD in group A during Retest Stimulation 1—6 (day
four) was 58.5  3.6 s, compared to 56.6  5.2 s
during Retest Stimulation 7—12 (day five) (Fig. 1).
Median seizure rank in group A was stage 5 during
both retest paradigms and was not statistically
different (Fig. 2) (Wilcoxon, Mann—Whitney). Like-
wise, mean ADD in group B showed no statistically
significant differences between the two retest para-
digms: mean ADD during Retest Stimulation 1—6 was
49.3  4.3 s compared to 42.1  6.0 s during Retest
Stimulations 7—12 (Fig. 1). Median seizure rank forgroup B was stage 5 during both retest paradigms
and no statistical differences were seen (Fig. 2)
(Wilcoxon, Mann—Whitney). One rat from group B
was removed from the experiment and statistical
processing because it did not show consistent stage
5 responses during Retest Stimulations 7—12. During
Retest Stimulations 7—9 this rat only showed stage
1—2 responses and during the subsequent Retest
Stimulations 10—12 it only displayed stage 4 sei-
zures.
Following the retest paradigm on day four of the
experiment, rats from group A (n = 4) were adminis-
tered TPM while rats from group B (n = 3) received
only vehicle. Consequently, kindling parameters
were not statistically different in group B following
the injection: mean ADD and median seizure rank
during Postdrug Stimulations 1—6 were 52.1  5.2 s
and stage 5, respectively (Figs. 1 and 2). The rats
from group A did show a significant reduction in both
ADD and seizure severity during Postdrug Stimula-
tions 1—6 compared to the results from these rats
during Retest Stimulations 1—6: mean ADD dropped
to 27.1  3.4 s (Fig. 1) and mean seizure rank
declined to stage 4 ( p < 0.05) (Fig. 2) (Wilcoxon).
Following the retest paradigm performed on day
five of the experiment, rats from group A received
only vehicle while rats from group B were injected
with TPM. Again, kindling parameters did not show
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administration of vehicle: mean ADD and median
seizure rank in rats from group A remained at
54.1  5.5 s and stage 5. Rats from group B did show
a noticeable decline in seizure characteristics dur-
ing Postdrug Stimulations 7—12 compared to the
results of these rats during the Retest Stimulations
7—12: mean ADD was reduced to 9.3  1.5 s and
median seizure rank dropped to stage 4 (p < 0.05)
(Figs. 1 and 2) (Wilcoxon).Discussion
The use of kindling as a first line evaluation tool in
the anti-epileptic screening procedure is hampered
by its laborious and time-consuming nature. Tradi-
tional kindling protocols usually provide once- or
twice-daily stimulations and can take weeks to
accomplish. In their original publications, Lothman
and coworkers described the serial day rapid kind-
ling procedure used in this experiment and found
that the serial day RKRHS protocol renders fully
kindled animals faster than traditional kindling
but only leads to a short lasting fully kindled state
that gradually dissipates over the course of several
days. This not only raised concerns whether this
model compares to traditional kindling but inevita-
bly also whether this model could be used in the AED
screening procedure.12—14,17
The main goal of this study was to further inves-
tigate the potential benefit of using serial day rapid
kindling as a fast and reliable screening model in the
validation procedures for AEDs with a minimal
amount of animals. In this experiment, eight rats
were fully kindled within 36 stimulations, meaning
that by the end of the third day of the RKRHS
protocol, a batch of rats had become available for
the screening procedure. By using a cross-over
design, each rat served as control animal at one
time and as treated animal at another.
During both retest paradigms, 7 out of 8 rats
displayed consistent complex partial seizures in
response to kindling stimulation. Both seizure stage
and ADD did not change significantly during the
retest procedures, indicating that a stable kindled
state had been induced. Serial day rapid kindling
therefore presents the researcher with the possibi-
lity to induce a sufficiently long lasting epileptic
state in rats in a matter of days. This alternative
takes up less time compared to traditional kindling
protocols with once-daily stimulation and still
results in a fully kindled state that persists long
enough for drug testing.
The drug screening protocol performed in this
experiment has shown that TPM administrationresults in a significant amelioration of seizure para-
meters in this model. Following TPM administration,
epileptiform activity showeda drastic decline in both
severity and duration. Mean ADD showed an average
decline of 54% in group A and 78% in group B
(p < 0.05). Likewise, the rats displayed more mod-
erate seizures following administration of TPM
(p < 0.05). In this experiment, treatment with
TPM (100 mg/kg, i.p.) did not readily suppress (lim-
bic) seizure generation but did limit seizure duration
(measured by the ADD) and reduced seizure spread
(measuredby the amelioration of seizure semiology).
The experiment also provides some insight into
the duration of the anticonvulsive effects of a single
i.p. administration of TPM. TPM has a prolonged
half-life of 21 h, meaning that some residual antic-
onvulsant effects of earlier TPM administration (on
day 4) could have resulted in a noticeable carry-over
effect during the subsequent testing period (on day
5). No such effects were noted in this experiment. It
might however be wise to expand the interval
between subsequent testing periods in the cross-
over design to at least two times the half-life period.
Whether the kindled state elicited by the serial day
rapid kindling design is stable enough to bridge
between more distanced testing periods, remains
to be determined.
The results of this study confirm that TPM is a
potent anti-epileptic drug and provide additional
proof of the usability of the serial day rapid kindling
protocol as a reliable screening tool. In a previous
study, this protocol has also been successfully used
to study the effect of levetiracetam, another recent
anti-epileptic drug.15 Taken together, both studies
suggest serial day rapid kindling could be forwarded
in the drug screening process to allow for a more
detailed analyses of compounds earlier in preclini-
cal development.
In conclusion, rats kindled according to the serial
day rapid kindling protocol displayed a stable fully
kindled state that allows a cross-over AED screening
procedure. TPM was shown to be an effective anti-
epileptic drug in serial day rapid kindling. This
model proved to be an effective tool in screening
drugs for anti-epileptic properties, yielding results
over the course of only a few days.Acknowledgments
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